Search clinical trials for: AZD4076

Total 48 results

AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca

Completed

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

T2DM With NAFLD
AstraZeneca

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Spain, Canada, United Kingdom, Italy, Germany, Australia, United States, Taiwan, France, Korea, Republic of, China
AstraZeneca

Completed

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins Lymphoma

Italy, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
AstraZeneca

Terminated

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Lymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic Malignancies

United States
AstraZeneca

Terminated

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Lymphoma | Non-Hodgkin Lymphoma | NHL

United States
AstraZeneca

Completed

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Neoplasms

United States
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Terminated

AZD8075 Single Ascending Dose Study

Healthy Volunteers

Sweden
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
AstraZeneca

Terminated

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Lymphoma

United States, Canada
AstraZeneca

Terminated

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
AstraZeneca

Withdrawn

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

Healthy
AstraZeneca

Withdrawn

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 (PET)

Healthy

Sweden
AstraZeneca
Quintiles, Inc.

Terminated

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity (NP-MH)

Neuropathic Pain | Mechanical Hypersensitivity

United States
AstraZeneca

Completed

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

Healthy
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
AstraZeneca

Completed

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Pain | Diabetic Neuropathy

United States
AstraZeneca

Completed

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

Rheumatoid Arthritis

United Kingdom
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
AstraZeneca

Completed

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Pain

United Kingdom
AstraZeneca

Recruiting

A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin Lymphoma

Korea, Republic of, United States, Japan, Australia, Taiwan
AstraZeneca
Altasciences Company Inc.

Completed

A Safety Study of AZD4041 in Healthy Participants

Opioid Use Disorder (OUD)

Canada
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
AstraZeneca

Completed

14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations

Reflux Episodes

Netherlands
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

Pain

Sweden
University of Leeds

Completed

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)

Diabetes Mellitus, Type 2

United Kingdom
AstraZeneca

Completed

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Raised Intraocular Pressure

Sweden, United States, United Kingdom
AstraZeneca
Parexel

Active, not recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
AstraZeneca

Completed

A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers

Healthy Volunteers

Germany
AstraZeneca

Completed

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Opioid Use Disorder

United States
AstraZeneca

Completed

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States, Mexico, Poland, Romania, Canada, Argentina, Australia, Slovakia, France, Czech Republic, Belgium, Russian Federation
AstraZeneca

Terminated

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Haematological Malignancies

France, Italy, United States, Korea, Republic of, Germany, Australia
AstraZeneca

Withdrawn

A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis
AstraZeneca

Terminated

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Pablo Tebas
AstraZeneca; Inovio Pharmaceuticals; The Wistar Institute

Recruiting

dMAbs for Prevention of COVID-19

Healthy Volunteers

United States
University of Oxford
AstraZeneca

Completed

Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)

Iatrogenic Cushing's Disease

United Kingdom
Dr. Frank Arguello Cancer Clinic
Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia...

Recruiting

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Neoplasms

Mexico
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

Conditioning | Haploidentical Stem Cell Transplantation

China
AstraZeneca

Completed

AZD2066 Cocktail Study

Chronic Pain

United Kingdom

3

Subscribe